SEC
SlamSEC
Search
Browse
Earnings
Rallybio Corp — SlamSEC
Rallybio Corp
Nasdaq:
RLYB
Pharmaceutical Preparations
·
NEW HAVEN, CT
Overview
All Filings
Sum Fin
Credit
Insiders
Governance
Overview
All Filings
Sum Fin
Credit
Insiders
Governance
Summary Financials
Revenue
$600,000
FY 2024
Adj. EBITDA
-$78.8M
-13130.3% margin
FY 2024
Net Income
-$74.6M
-12427.3% margin
FY 2024
EPS (Diluted)
-$1.84
FY 2024
Stock Price
$10.82
+0.0%
2026-03-09
52W Range
$1.76 – $11.49
P/E Ratio
-5.9x
Market Cap
$457.1M
Cash
$24.5M
FY 2024
Total Debt
—
Net Cash
$24.5M
FY 2024
Enterprise Value
$432.6M
Debt / EBITDA
0.3x
FY 2024
EV / EBITDA
-5.5x
Employees
—
CFO
Lieber Jonathan I